NorthWest Biotherapeutics Inc (NWBO)

[LessIsMore]

Look at how Telix kept their shareholders updated, what a concept!!

Progress in 2024
Grow Illuccix® revenue globally
Focus on driving adoption and increasing market share of Illuccix® in our commercial markets, including the U.S.
Expand into new geographies through submission of new product marketing applications
• Illuccix® global revenue $357.9 million up 64% on H1 20231
• European Union (EU) marketing authorisation application
(MAA): All regulator questions raised during standard review
"clock-stop" period have been addressed2
• United Kingdom (UK) MAA: Regulator's assessment report
received subsequent to reporting period, with no substantive
issues raised
• EU and UK MAA decisions expected in H2 2024
• Brazil MAA: In final stages of regulatory review, approval
decision anticipated during Q3 20242
• Pivotal Phase III registration study in China intended to bridge
to FDA approval of Illuccix®: Surpassed 75% enrolme